BR112023019105A2 - Métodos para predizer e modular a glicação de uma proteína - Google Patents

Métodos para predizer e modular a glicação de uma proteína

Info

Publication number
BR112023019105A2
BR112023019105A2 BR112023019105A BR112023019105A BR112023019105A2 BR 112023019105 A2 BR112023019105 A2 BR 112023019105A2 BR 112023019105 A BR112023019105 A BR 112023019105A BR 112023019105 A BR112023019105 A BR 112023019105A BR 112023019105 A2 BR112023019105 A2 BR 112023019105A2
Authority
BR
Brazil
Prior art keywords
glycation
methods
percentage
predicting
rates
Prior art date
Application number
BR112023019105A
Other languages
English (en)
Inventor
Douglas Kamen
Haibo Qiu
Kenneth Graham
Teng-Chieh Yang
Xiaobin Xu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112023019105A2 publication Critical patent/BR112023019105A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

métodos para predizer e modular a glicação de uma proteína. as modalidades fornecem métodos para prever a porcentagem de glicação de um aminoácido em uma biomolécula terapêutica. em um exemplo, um método para prever uma percentagem de glicação de um aminoácido em uma biomolécula inclui a determinação de um primeiro conjunto de taxas para uma reação de desglicação para um primeiro conjunto de temperaturas, inferindo um segundo conjunto de uma ou mais taxas para a reação de desglicação para um segundo conjunto de temperaturas e usando o segundo conjunto de uma ou mais taxas para prever a porcentagem de glicação a qualquer temperatura correspondente ao segundo conjunto de temperaturas e ao longo de qualquer período de tempo. também são fornecidos métodos para manter uma porcentagem de glicação de um aminoácido dentro de uma faixa de porcentagem de glicação predeterminada ao longo do prazo de validade de uma biomolécula terapêutica e métodos para reduzir ou aumentar a potência de uma biomolécula terapêutica em um indivíduo no momento da administração.
BR112023019105A 2021-04-02 2022-04-01 Métodos para predizer e modular a glicação de uma proteína BR112023019105A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163170330P 2021-04-02 2021-04-02
PCT/US2022/023127 WO2022212889A1 (en) 2021-04-02 2022-04-01 Methods for predicting and modulating glycation of a protein

Publications (1)

Publication Number Publication Date
BR112023019105A2 true BR112023019105A2 (pt) 2023-12-05

Family

ID=81750467

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019105A BR112023019105A2 (pt) 2021-04-02 2022-04-01 Métodos para predizer e modular a glicação de uma proteína

Country Status (13)

Country Link
US (1) US20220326250A1 (pt)
EP (1) EP4314839A1 (pt)
JP (1) JP2024514500A (pt)
KR (1) KR20230165800A (pt)
CN (1) CN117295951A (pt)
AR (1) AR125255A1 (pt)
AU (1) AU2022249176A1 (pt)
BR (1) BR112023019105A2 (pt)
CA (1) CA3213363A1 (pt)
IL (1) IL305946A (pt)
MX (1) MX2023011063A (pt)
TW (1) TW202305368A (pt)
WO (1) WO2022212889A1 (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
US8546144B2 (en) * 2010-11-17 2013-10-01 Streck, Inc. Method of preparing controls for glycated hemoglobin S-A1c derived from healthy blood cells

Also Published As

Publication number Publication date
AR125255A1 (es) 2023-06-28
IL305946A (en) 2023-11-01
EP4314839A1 (en) 2024-02-07
AU2022249176A9 (en) 2023-10-19
JP2024514500A (ja) 2024-04-02
CN117295951A (zh) 2023-12-26
WO2022212889A1 (en) 2022-10-06
MX2023011063A (es) 2023-11-22
CA3213363A1 (en) 2022-10-06
TW202305368A (zh) 2023-02-01
KR20230165800A (ko) 2023-12-05
US20220326250A1 (en) 2022-10-13
AU2022249176A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
Sauls et al. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia
Österberg et al. Regulation of alternative sigma factor use
Colin et al. Mammalian frataxin controls sulfur production and iron entry during de novo Fe4S4 cluster assembly
Flühe et al. Two [4Fe-4S] clusters containing radical SAM enzyme SkfB catalyze thioether bond formation during the maturation of the sporulation killing factor
Kirkwood Accuracy in Molecular Processes: Its Control and Relevance to Living System
Jiang et al. Reconstitution of the signal-transduction bicyclic cascade responsible for the regulation of Ntr gene transcription in Escherichia coli
Søgaard‐Andersen et al. Coupling gene expression and multicellular morphogenesis during fruiting body formation in Myxococcus xanthus
Chiu et al. Glutamine stimulates mTORC1 independent of the cell content of essential amino acids
Sharma et al. Probing the different chaperone activities of the bacterial HSP70‐HSP40 system using a thermolabile luciferase substrate
Yung et al. Diffusion of interleukin‐2 from cells overlaid with cytocompatible enzyme‐crosslinked gelatin hydrogels
Belalcázar et al. Transsulfuration is a significant source of sulfur for glutathione production in human mammary epithelial cells
Alavi Targeted OMA1 therapies for cancer
Huang et al. CHO cell productivity improvement by genome-scale modeling and pathway analysis: Application to feed supplements
Haselwandter et al. Formation and stability of synaptic receptor domains
Raychaudhuri et al. Chemical mechanism and substrate specificity of RhlI, an acylhomoserine lactone synthase from Pseudomonas aeruginosa
Zhang et al. Direct simulation of early-stage Sec-facilitated protein translocation
Fitzgerald et al. Re-engineering cellular physiology by rewiring high-level global regulatory genes
BR112023019105A2 (pt) Métodos para predizer e modular a glicação de uma proteína
Sánchez et al. Metataxonomic and metabolomic evidence of biofilm homeostasis disruption related to caries: An in vitro study
Bachmann et al. Kinetic mechanism of the β-lactam synthetase of Streptomyces clavuligerus
BR112017011012A2 (pt) método baseado em célula para determinar a potência de defibrotide
Oshlag et al. Mild hyperthermia enhances the expression and induces oscillations in the Dicer protein
Henry et al. The antioxidant TEMPOL protects human hematopoietic stem cells from culture-mediated loss of functions
Hoskins et al. The formylglycinamide ribonucleotide amidotransferase complex from Bacillus subtilis: metabolite-mediated complex formation
Shadrick et al. Kinetics of DNA unwinding by the RecD2 helicase from Deinococcus radiodurans